7 Hills Pharma

7 Hills Pharma

Biotechnology, 2450 Holcombe BLVD, Houston, Texas, 77021, United States, 1-10 Employees

7hillspharma.com

  • facebook
  • LinkedIn

phone no Phone Number: +17*********

Who is 7 HILLS PHARMA

7 Hills Pharma is a clinical-stage pharmaceutical company developing first-in-concept, oral immune stimulants to augment a broad range of immunotherapies for the treatment of drug-resista...

Read More

map
  • 2450 Holcombe BLVD, Houston, Texas, 77021, United States Headquarters: 2450 Holcombe BLVD, Houston, Texas, 77021, United States
  • 1995 Date Founded: 1995
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from 7 HILLS PHARMA

7 Hills Pharma Org Chart and Mapping

Employees

Rob Bent

Chief Financial Officer

Siddhartha De

Senior Director, Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding 7 Hills Pharma

Answer: 7 Hills Pharma's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 77021, United States

Answer: 7 Hills Pharma's phone number is +17*********

Answer: 7 Hills Pharma's official website is https://7hillspharma.com

Answer: 7 Hills Pharma's revenue is Under $1 Million

Answer: 7 Hills Pharma's SIC: 2834

Answer: 7 Hills Pharma's NAICS: 325412

Answer: 7 Hills Pharma has 1-10 employees

Answer: 7 Hills Pharma is in Biotechnology

Answer: 7 Hills Pharma contact info: Phone number: +17********* Website: https://7hillspharma.com

Answer: 7 Hills Pharma is a clinical-stage pharmaceutical company developing first-in-concept, oral immune stimulants to augment a broad range of immunotherapies for the treatment of drug-resistant solid tumors and prevention of infectious diseases. Our compounds are selective, allosteric, systemic activators of the integrins LFA-1 and VLA-4 that have been shown in preclinical models to augment the effectiveness of prophylactic vaccines for influenza, COVID-19, Tuberculosis, and Chagas disease, as well as checkpoint inhibitors for solid tumors. Our lead molecule, 7HP349, has completed a Phase I first-in-human clinical trial, demonstrating oral bioavailability and an exceptional safety profile at exposures well exceeding therapeutic levels.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access